Stock · M12.DE · Healthcare
Germany · Small Cap · Revenue 12 mo. €257.4M
Price as of 11/06/2026
M1 Kliniken AG, together with its subsidiaries, provides aesthetic medicine and plastic surgery services in Germany, Austria, the Netherlands, Switzerland, Croatia, Hungary, Bulgaria, and Romania.
M1 Kliniken AG, together with its subsidiaries, provides aesthetic medicine and plastic surgery services in Germany, Austria, the Netherlands, Switzerland, Croatia, Hungary, Bulgaria, and Romania. It operates through Beauty and Trade segments. The Beauty segment provides aesthetic surgery services, such as breast augmentation, eyelid lifts, and liposuction; and other aesthetic medical treatment services, including injections with hyaluronic acid and botulinum toxin. This segment also manages a private clinic for plastic and aesthetic surgery; and medical specialist centers for aesthetic and plastic medicine under the Schlossklinik and M1 Med Beauty names. The Trade segment sells pharmaceuticals and medical products for various therapeutic areas of oncology, HIV/AIDS, neurology, rheumatology, other chronic diseases, and aesthetic medicine. The company was incorporated in 2007 and is based in Berlin, Germany. M1 Kliniken AG is a subsidiary of MPH Health Care AG.
Original text from the data provider
Summary
60.2 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
Required FCF growth per year
no growth
no growth afterwards
Price to operating cash flow 15.3×, within its usual range.
Middle half of 20 quarters: 8.0× to 15.4×, median 9.7×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
No anomaly in the stored figures.
Since the last quarter
Q1 → Q3 2026
2 more unchanged: FCF margin, Shares outstanding
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 18.45% | 11.52% | Rank 74 |
| Return on capital (Greenblatt) | 54.78% | 32.55% | Rank 73 |
| EBIT margin | 10.09% | 18.31% | Rank 27 |
| FCF margin | 10.39% | 14.12% | Rank 36 |
| Gross margin | 13.02% | 60.99% | Rank 5 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 7.40% | 8.04% | Rank 48 |
| Earnings growth, 3 years per year | 71.68% | 5.44% | Rank 95 |
| Earnings growth, 5 years per year | 26.57% | 7.00% | Rank 90 |
| Sustainable growth (ROE × retained earnings) | −1.11% | 3.66% | Rank 0 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 6.26% | 2.90% | Rank 89 |
| FCF yield | 10.62% | 3.63% | Rank 95 |
| EV/saleslower is better | 0.89 | 4.03 | Rank 88 |
| EV/EBITlower is better | 8.83 | 21.73 | Rank 98 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | 22.94% | 8.66% | Rank 71 |
| Share price, 6 months | 10.28% | 24.27% | Rank 28 |
| Share price, 3 months | 4.30% | 15.42% | Rank 24 |
| Distance from 52-week high | −10.52% | −7.35% | Rank 38 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | −5.84% | 0.30% | Rank 87 |
| Change in share countlower is better | 0.00% | 0.00% | Rank 45 |
| Dividend streak in years | 1 | 10 | Rank 29 |
| Price reaction to results, market-adjusted | 4.80% | 0.05% | Rank 85 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 63.36% | 48.40% | Rank 72 |
| Net debt/EBITDAlower is better | −0.78 | 1.11 | Rank 81 |
| Debt to equitylower is better | 0.09 | 0.48 | Rank 82 |
| Volatility, 1 yearlower is better | 39.34% | 31.42% | Rank 27 |
Ten years in figures
| Year | Revenue, €M | EBIT margin | FCF | Shares | Net debt, €M |
|---|---|---|---|---|---|
| 2016 | 36.0 | 12.1% | €7.1M | 15.0M | −5.8 |
| 2017 | 47.2 | 11.8% | −€1.2M | 15.4M | −14.5 |
| 2018 | 65.2 | 9.8% | €764.5K | 16.8M | −25.2 |
| 2019 | 77.2 | 10.1% | −€6.7M | 17.5M | 2.3 |
| 2020 | 159.6 | 2.8% | €8.1M | 18.6M | 17.4 |
| 2021 | 314.6 | 3.9% | €14.3M | 18.6M | −6.9 |
| 2022 | 285.3 | 3.3% | €19.0M | 18.3M | −15.5 |
| 2023 | 316.3 | 5.0% | €6.8M | 19.1M | −5.3 |
| 2024 | 339.2 | 7.9% | €29.6M | 18.6M | −11.0 |
| 2025 | 364.3 | 10.1% | €37.8M | 18.6M | −27.5 |
5 of 7 StockScorer Score rules met · How the score is built
M1 Kliniken AG mainly meets criteria in the Valuation category. Result from 18 strategies checked.
M1 Kliniken AG is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
5 of 7 rules met
7 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for M1 Kliniken AG.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 16.0 | 30.0 |
| P/B ratio | 2.9 | 4.8 |
| Return on equity (ROE) | 18.5% | 11.5% |
| Equity ratio | 63.4% | 48.4% |
| Debt-to-equity (D/E) | 0.09 | 0.48 |
| Dividend yield | 6.3% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| M12.DE | M1 Kliniken AGthis page | |
| HSIC | Henry Schein Inc | Low4.5 |
| SIG.AX | Sigma Healthcare Ltd | locked |
| CAH | Cardinal Health Inc | Medium5.5 |
| COR | Cencora Inc. | locked |
| MCK | McKesson Corporation | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.